Publications by authors named "Stephan A Veltkamp"

Claim this Profile
P
Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.
Suzanne Leijen, Stephan A Veltkamp, Alwin D R Huitema, E van Werkhoven, Jos H Beijnen

Gynecol Oncol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes.
Ele Ferrannini, Stephan A Veltkamp, Ronald A Smulders, Takeshi Kadokura

Diabetes Care· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
Stephan A Veltkamp, Jan van Dijk, Christiane Collins, Michel van Bruijnsvoort, Takeshi Kadokura

Clin Ther· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects.
Stephan A Veltkamp, Takeshi Kadokura, Walter J J Krauwinkel, Ronald A Smulders

Clin Drug Investig· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors.
Stephan A Veltkamp, Els O Witteveen, Angela Capriati, Attilio Crea, Fabio Animati

Clin Cancer Res· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice.
Stephan A Veltkamp, Dick Pluim, Olaf van Tellingen, Jos H Beijnen, Jan H M Schellens

Drug Metab Dispos· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine.
Stephan A Veltkamp, Dick Pluim, Maria A J van Eijndhoven, Maria J Bolijn, Felix H G Ong

Mol Cancer Ther· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study.
Stephan A Veltkamp, Robert S Jansen, Sophie Callies, Dick Pluim, Carla M Visseren-Grul

Clin Cancer Res· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy.
Stephan A Veltkamp, Jos H Beijnen, Jan H M Schellens

Oncologist· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183.
Linda E Bröker, Stephan A Veltkamp, Elisabeth I Heath, Bart C Kuenen, Helen Gall

Clin Cancer Res· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel.
Stephan A Veltkamp, Jetske M Meerum Terwogt, Michel M van den Heuvel, Hester H van Boven, Jan H M Schellens

Invest New Drugs· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis